EVMN (Evommune, Inc.) Stock Financials & Earnings | Market Cap Arena

EVMN (Evommune, Inc.) Stock Financials & Earnings | Market Cap Arena

EVMNEvommune, Inc.

Mkt Cap$319M

Healthcare·Biotechnology·🇺🇸 United States·NYSE

Revenue (TTM)$13M

Net Income (TTM)-$59M

EPS (TTM)-$2.80

Free Cash Flow (TTM)-$82M

Gross Margin91.8%

Op. Margin-541.1%

Net Margin-453.2%

FCF Margin-632.6%

P/S Ratio (TTM)24.5x

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Next: Q4 2025 · Mar 26

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 24	$7M	$7M	-$4M
Q2 24	$0	-$325K	-$28M
Q4 24	$0	$0	-$19M
Q1 25	$3M	$3M	-$15M
Q2 25	$0	-$375K	-$23M
Q3 25	$10M	$10M	-$13M

Valuation

Quarter	P/S	P/E
Q1 24	—	—
Q2 24	—	—
Q4 24	—	—
Q1 25	31.9x	—
Q2 25	106.3x	—
Q3 25	24.5x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 24	-$5M	-$5M
Q2 24	-$9M	-$9M
Q4 24	-$22M	-$22M
Q1 25	-$24M	-$24M
Q2 25	-$26M	-$26M
Q3 25	-$10M	-$10M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 24	$70K
Q2 24	$18K
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$131K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 25	-100.0%	+113.8%
Q3 25	—	-17.5%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 24	$0	0.0%
Q2 24	$0	—
Q4 24	$448K	—
Q1 25	$0	0.0%
Q2 25	$0	—
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 24	$8M	—	—	$3M
Q2 24	$25M	—	—	$3M
Q4 24	$16M	$2M	$1M	—
Q1 25	$14M	—	—	$3M
Q2 25	$20M	$3M	—	—
Q3 25	$20M	—	—	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 24	$16M	$56M	$72M
Q1 25	$6M	$43M	$48M
Q2 25	$62M	$25M	$87M
Q3 25	$27M	$49M	$76M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 24	30M	—
Q2 24	30M	+0.0%
Q4 24	13M	-56.8%
Q1 25	30M	+131.6%
Q2 25	30M	+0.0%
Q3 25	32M	+4.8%